Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 4, 2014, Pages 560-563

  Price, M J ^a   Baker, B A ^b   Jakubowski, J A ^c   Li, W ^b   Heiselman, D E ^c   Angiolillo, D J ^d  

^a SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^b DAIICHI SANKYO INC   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Clopidogrel; Platelet aggregation; Platelet aggregation inhibitors; Platelet function tests; Prasugrel; Thienopyridine

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; THIENOPYRIDINE DERIVATIVE; P2RY12 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PURINERGIC P2Y12 RECEPTOR; PYRIDINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG EFFECT; DRUG IDENTIFICATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PLATELET REACTIVITY; POINT OF CARE TESTING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THROMBOCYTE FUNCTION ANALYZER; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL; CYTOLOGY; DRUG ADMINISTRATION; FEMALE; HOSPITAL INFORMATION SYSTEM; MALE; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; THROMBOCYTE; THROMBOCYTE ACTIVATION; TIME; TREATMENT OUTCOME;

AGED; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET ACTIVATION; POINT-OF-CARE SYSTEMS; PYRIDINES; RECEPTORS, PURINERGIC P2Y12; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; THIOPHENES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84898050402     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12505     Document Type: Article

References (10)

1. Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 2006; 98: 681-4.
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16.
3. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, van Werkum JW, Paganelli F, Price MJ, Waksman R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-33.
4. Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim H-S, Patti G, Breet NJ, DiSciascio G, Cuisset T, Dangas G. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58: 1945-54.
5. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124: 1132-7.
6. Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD, for the A-DESI. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382: 614-23.
7. Price MJ, Walder JS, Baker BA, Heiselman DE, Jakubowski JA, Logan DK, Winters KJ, Li W, Angiolillo DJ. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the Recovery Trial. J Am Coll Cardiol 2012; 59: 2338-43.
8. Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009; 119: 2625-32.
9. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305: 1097-105.
10. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrie D, Boueri Z, Belle L, van Belle E, Rousseau H, Aubry P, Monsegu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-9.